Dopamine D2 and D4 receptor ligands:: relation to antipsychotic action

被引:64
作者
Wilson, JM
Sanyal, S
Van Tol, HHM
机构
[1] Clarke Inst Psychiat, Lab Mol Neurobiol 3, Toronto, ON M5T 1R8, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[3] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[4] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
基金
英国医学研究理事会;
关键词
antipsychotic; clozapine; schizophrenia; dopamine D-4 receptor antagonist; neuroleptic loose; dopamine receptor; extrapyramidal symptom; dopamine D-2-like receptor;
D O I
10.1016/S0014-2999(98)00312-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since the discovery that the antipsychotic action of phenothiazines was mediated by dopamine D-2 receptors, the dopamine system has been scrutinized for schizophrenia related abnormalities. The focus has been to create neuroleptics with improved antipsychotic profiles and reduced side effects. With the identification of multiple dopamine receptor subtypes, the hypotheses regarding the role of dopamine in schizophrenia and antipsychotic action of neuroleptics have been refined. Even after the molecular identification of newer dopamine D-2-like receptor subtypes (D-3 and D-4), the dopamine D-2 receptor is still considered the predominant site for antipsychotic action. However, there has been much debate concerning the modulatory role of other dopamine receptor sites in the mechanism of action of antipsychotic drugs. Specifically, the dopamine D-4 receptor has received much attention in this regard, since the atypical antipsychotic agent, clozapine, preferentially blocks this receptor subtype as compared with dopamine D-2 and D-3 receptors. In this review we will highlight some of the observations and arguments regarding the involvement of the dopamine D-2 and D-4 receptor sites in the therapeutic efficacy of antipsychotic medication. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:273 / 286
页数:14
相关论文
共 123 条
  • [91] ANTIPSYCHOTIC DRUG DOSES AND NEUROLEPTIC-DOPAMINE RECEPTORS
    SEEMAN, P
    LEE, T
    CHAUWONG, M
    WONG, K
    [J]. NATURE, 1976, 261 (5562) : 717 - 719
  • [92] Seeman P, 1997, SYNAPSE, V25, P137
  • [93] HUMAN-BRAIN D1 AND D2 DOPAMINE-RECEPTORS IN SCHIZOPHRENIA, ALZHEIMERS, PARKINSONS, AND HUNTINGTONS DISEASES
    SEEMAN, P
    BZOWEJ, NH
    GUAN, HC
    BERGERON, C
    REYNOLDS, GP
    RIEDERER, P
    JELLINGER, K
    TOURTELLOTTE, WW
    BIRD, ED
    [J]. NEUROPSYCHOPHARMACOLOGY, 1987, 1 (01) : 5 - 15
  • [94] DOPAMINE D4 RECEPTORS ELEVATED IN SCHIZOPHRENIA
    SEEMAN, P
    GUAN, HC
    VANTOL, HHM
    [J]. NATURE, 1993, 365 (6445) : 441 - 445
  • [95] SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261
  • [96] Therapeutic receptor-blocking concentrations of neuroleptics
    Seeman, P
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 : 5 - 13
  • [97] SEEMAN P, 1909, IN PRESS MOL PSYCHIA
  • [98] DOPAMINE-D4 RECEPTOR SUBTYPES AND RESPONSE TO CLOZAPINE
    SHAIKH, S
    COLLIER, D
    KERWIN, RW
    PILOWSKY, LS
    GILL, M
    XU, WM
    THORNTON, A
    [J]. LANCET, 1993, 341 (8837) : 116 - 116
  • [99] AMPHETAMINE PSYCHOSIS - MODEL SCHIZOPHRENIA MEDIATED BY CATECHOLAMINES
    SNYDER, SH
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1973, 130 (01) : 61 - 67
  • [100] MOLECULAR-CLONING AND CHARACTERIZATION OF A NOVEL DOPAMINE RECEPTOR (D3) AS A TARGET FOR NEUROLEPTICS
    SOKOLOFF, P
    GIROS, B
    MARTRES, MP
    BOUTHENET, ML
    SCHWARTZ, JC
    [J]. NATURE, 1990, 347 (6289) : 146 - 151